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FibroscanAbstract Aim of the work: The association between hepatitis C virus (HCV)-related vasculitis and
severe hepatic ﬁbrosis is a controversial issue. In this study, we aimed to evaluate the liver affection
in a group of patients with HCV-related vasculitis and a control group with chronic HCV infection
without vasculitis.
Patients and methods: Twenty-six HCV associated vasculitis patients (22 females, 4 males) with a
mean age of 51.9 ± 8.5 years (range 36–72 years) and a control group including 20 age- and sex
matched HCV infected patients without any extra-hepatic autoimmune manifestations were
recruited in this study. All patients and controls were evaluated by routine biochemical tests,
conventional ultrasonography and Fibroscan.
Results: The mean disease duration in patients with vasculitis and the control group was
7.5 ± 7.3 and 4.1 ± 3.6 years, respectively (p= 0.062). Mean aspartate aminotransferase, bilirubin
and international normalized ratio (INR) values were higher in the control group (p= 0.036, 0.041
and 0.017, respectively). Hepatomegaly was found in 11 (42.3%) vasculitis patients and 17 (85%)
controls (p= 0.006), while portal hypertension was found in 4 (15.4%) vasculitis patients and 9
(45%) controls (p= 0.046). On Fibroscan, eleven vasculitis patients (42.3%) had mild to moderate
liver ﬁbrosis (F1–2), and 10 (38.5%) had severe liver ﬁbrosis (F3–4), while only one patient (5%) of
the control group had mild, and 17 (85%) had severe liver ﬁbrosis (p= 0.002).
Conclusion: Patients with chronic HCV infection without vasculitis have worse liver functions
and more advanced liver ﬁbrosis than those with HCV related vasculitis.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Chronic infection with the hepatitis C virus (HCV) is
associated with a wide spectrum of clinical manifestationswhich include hepatic and extrahepatic disorders. Liver
diseases may range from asymptomatic minimal histologic
changes with normal or near normal liver enzymes to
end-stage cirrhosis and hepatocellular carcinoma [1].
Mixed cryoglobulinemia (MC) is the most documented
extrahepatic manifestation of HCV infection and presents a
clinical triad of purpura, arthralgia and weakness with associ-
ated cryoglobulins. These are composed of different immuno-
globulins, with a monoclonal component in type II and only
188 A.A. Shahin et al.polyclonal immunoglobulins in type III [1,2] in addition to
viral core proteins and RNA, suggesting that cryoglobulin
formation results from the host immune response against
chronic HCV infection [3]. Although between 12% and 56%
of HCV infected patients have circulating cryoglobulins in
serum, only about 2–50% of those develop symptoms [3–5].
The development of cryoglobulinemic vasculitis has been asso-
ciated with type II cryoglobulinemia. Eighty percent of the
monoclonal rheumatoid factors (mRF) of type II cryoglobu-
linemia are unique to patients with HCV infection and are
hypothesized to be driven by the HCV infection and are
termed WamRF [6]. The pathological hallmark of MC is a
leukocytoclastic vasculitis, involving small and medium-sized
vessels responsible for cutaneous and visceral organ involve-
ment [7]. In addition to the classic MC syndrome, systemic
vasculitis related to HCV infection in the absence of detectable
cryoglobulins [8] as well as a polyarteritisnodosa- like vasculi-
tis have been described [9,10]. An epidemiological association
between MC and severe liver damage has been reported
[1,11]. On the other hand, Ferri [12] stated that chronic hepa-
titis in cryoglobulinemic vasculitis has usually a mild–moder-
ate clinical course and seems to be less severe if compared to
HCV-related chronic hepatitis without the MC syndrome.
Similarly, hepatocellular carcinoma less frequently complicates
MC syndrome compared to the whole population of HCV-
positive individuals. Since corticosteroids and immunosup-
pressive drugs are frequently needed to treat HCV related
vasculitis especially with major organ involvement [3], hepato-
toxicity in the presence of underlying liver pathology remains
of particular concern.
Liver biopsy has been the gold standard for staging of liver
ﬁbrosis, however, it is invasive and associated with some risks
such as pain and bleeding. In addition, a liver biopsy sample is
only a very small piece of the liver, which can lead to incorrect
staging if this sample is not representative of the rest of the
liver. Moreover, different pathologists can interpret the same
sample differently, which can result in discrepancies in liver
disease staging. Fibroscan (transient elastography) is a rela-
tively recent non-invasive method useful for staging of hepatic
ﬁbrosis. Essentially, the technology measures the velocity of
the sound wave passing through the liver and then converts
that measurement into a liver stiffness measurement. The
entire process is often referred to as liver ultrasonographic
elastography [13,14]. In this study, we aimed to study the liver
affection by conventional ultrasonography, Fibroscan and
routine biochemical tests in a group of patients with HCV-
related vasculitis and in a control group with HCV infection
without vasculitis.2. Patients and methods
Twenty-six HCV associated vasculitis patients and 20 age- and
sex matched chronically infected HCV control subjects
without any extra-hepatic autoimmune manifestations were
recruited in this study. The protocol of the research project
has been approved by the institution within which the work
was undertaken and it conforms to the provisions of the World
Medical Association’s Declaration of Helsinki.
The data recorded for every patient included the age, the
age of onset and the duration of HCV infection. The disease
duration for patients and controls was calculated from thetime of diagnosis of HCV infection; for patients in whom the
clinical manifestations of vasculitis preceded the diagnosis of
HCV infection, the disease duration was calculated from the
onset of vasculitis related symptoms.
The disease manifestations recorded for every patient were
as follows: the presence of arthralgia, arthritis, skin manifesta-
tions, neuro-psychiatric affection, cardiac, pulmonary, renal,
gastrointestinal, hepatic, ear, nose and throat (ENT), or
ophthalmologic involvement. According to the clinical presen-
tation, patients were classiﬁed as having medium or small sized
vessel vasculitis [15], (group A and group B, respectively).
Liver function tests included aspartate aminotransferase
(AST), alanine aminotransferase (ALT) (reﬂecting the micro-
inﬂammatory changes of the liver), serum albumin, total
bilirubin, prothrombin concentration (PC) and international
normalized ratio (INR) (reﬂecting the synthetic function of
the liver). All patients were evaluated for rheumatoid factor
(RF), antinuclear antibodies (ANA) and antibodies to anti-
double stranded nucleic acid (anti-dsDNA). Antineutrophil
cytoplasmicantibodies (ANCA) test was performed using indi-
rect immunoﬂuorescence assay on ethanol-ﬁxed neutrophils.
Cryoglobulins were isolated by centrifugation of refrigerated
patient’s serum in Wintrobe’s tubes. Positive cryoglobulinemia
was considered in patients who had a measurable cryocrit level
>1%. Complement components 3 and 4 (C3 and C4) were
assessed.
Exclusion criteria included: (1) hepatitis B virus (HBV)
patients by performing hepatitis B surface antigen (HbsAg)
and hepatitis B core antibody (HbcAb) tests using the enzyme
linked immunosorbent assay (ELISA) technique, (2) Human
Immunodeﬁciency virus (HIV) by performing anti-HIV-I and
-II antibody testing by ELISA technique, (3) coexistence of
autoimmune, lymphoproliferative or other infectious disease
(except HCV infection), (4) presence of any other cause of vas-
culitis, (5) any subject with other associated liver pathology as
Bilharziasis, (6) patients with conditions that interfere with the
reliability of Fibroscan measurement (morbidly obese subjects,
those with a large amount of chest wall fat or ascites) [13].
Real time ultrasound scanning was done using Toshiba,
Aplio MX device with convex probe, 3–5 MHz to measure
the liver size, to detect the presence of liver texture changes;
brightness, or cirrhosis (irregular surface, coarse texture, atten-
uated hepatic veins), signs of portal hypertension (presence of
abdominal collaterals, splenomegaly), ascites and to exclude
hepatic focal lesions.
Liver stiffness was measured by using Fibroscan. Up to ten
successful acquisitions were performed on each patient. Suc-
cess rate was calculated as the ratio of the number of successful
acquisitions over the total number of acquisitions. The median
value of successful measurements was kept as the representa-
tive of liver stiffness .Only the liver stiffness measurement
obtained with 10 successful acquisitions and a success rate of
at least 60% were considered reliable [16].
The relation between Fibroscan reading in K Pascal and the
stage of ﬁbrosis was considered as follows: F0 = 0:2.9,
F1 = 3:5.9, F2 = 6:8.9, F3 = 9:16.9 and F4 = 17:75 [17].
Statistical analysis was performed by SPSS (version 11) for
windows. The means and standard deviation (SD) were com-
puted for the continuous variables. The difference between
the means was tested by the standard t test. For comparison
of percentages, chi-squared (v2) test was used with Fisher’s
exact test. Mann–Whitney U test was used for comparison of
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icant when p value was less than 0.05.
3. Results
This study included 26 HCV vasculitis patients, 22 females
(84.6%) and 4 males (15.4%) with a male to female ratio of
0.182. The mean age was 51.9 ± 8.5 years with a range
between 36 and 72 years. Twenty age- and sex matched HCV
infected patients without any extra-hepatic autoimmune man-
ifestations were included as controls. They were 17 females
(85%) and 3 males (15%) with male to female ratio of 0.176.
Vasculitis was the presenting symptom in 24/26 patients
(92.3%). In 7 patients the diagnosis of HCV infection was
made during the laboratory work up of vasculitis. In 2 patients
the diagnosis of HCV infection preceded the onset of vasculitis
by 6 and 9 years. In the remaining 17 patients, HCV infection
was diagnosed after the onset of vasculitis by a mean of
5.7 ± 4.5 years (range from 1 to 18 years). Comparisons
between all vasculitis patients and controls and between group
A (medium-sized vessel vasculitis) and group B (small sized-
vessel vasculitis) concerning the demographic data are shown
in Table 1.
HCV was attributed to previous operation in 2 patients, to
blood transfusion in 1 patient, and to a dental procedure in 3
patients. Six patients (23.1%) were diabetic. Ten patients
(38.5%) were hypertensive. Patients were classiﬁed into two
groups according to the size of the vessel involved: group A;
patients with medium sized vessel vasculitis, they were 8
patients (30.8%), 3 of them had small vessel vasculitis in addi-
tion, and group B; patients with only small-sized vessel vascu-
litis, they were 18 patients (69.2%). Thirteen patients received
1–3 pulses of IV methylprednisolone (0.5–1 g/pulse) during
their illness. Sixteen patients had a history of receiving oral
prednisone (starting by 0.5 mg/kg with gradual tapering to
5–10 mg/day maintenance dose at the time of the study). Eight
patients started at low dose oral prednisone (5–10 mg/day). Six
patients received azathioprine (50–100 mg/day) during their ill-
ness. Ten patients received cyclophosphamide for 6 monthly
pulses with mean total dose 5500 ± 2387.5 mg (6 patients in
group A and 4 patients in group B).
The details of clinical and laboratory data of vasculitis
patients (all patients, group A and group B are shown in
Table 2. Symmetric poly-arthritis was seen in 3 patients of
group A and in 10 patients of group B. One patient (group
A) had asymmetric polyarthritis, and 2 other patients had
mono-arthritis (1 in group A and 1 in group B). Gangrene
occurred in the upper limbs in three patients (group A). Nerve
conduction velocity studies of the patients with peripheral neu-
ropathy revealed that 6 patients had axonal-demyelinating
lesions (group A). One patient had brain vasculitis (group A)Table 1 Comparisons between patients and controls and between g
HCV with vasculitis patients n= 26 Co
Age (years) 51.9 ± 8.5 53.
Disease duration (years) 7.5 ± 7.3 4.
Age at disease onset (years) 43.9 ± 10.7 49.
A: medium-sized vessel vasculitis; B: small-sized vessel vasculitis.
* Statistically signiﬁcant.and another had multiple infarcts (group B) as diagnosed by
magnetic resonance imaging (MRI). Cardiac involvement
was diagnosed in 4 patients; pericardial effusion was detected
in one patient (group A), valvular lesions and diastolic dys-
function in one patient (group B) and ischemic heart disease
in 2 patients (group B). None of the patients had mesenteric
or retinal vasculitis.
In ﬁve patients that had positive ANA, one had a homoge-
neous pattern (group B), and 4 patients had a speckled pattern
(one patient in group A and 3 patients in group B). None of
the patients had anti DNA antibodies or ANCA.
The details of liver function tests, sonographic features and
Fibroscan results are shown in Table 3. Elevated liver enzymes
were found in 10/26 patients with HCV vasculitis and in 12/20
of the control group at the time of the study. Eleven vasculitis
patients (42.3%) had mild to moderate liver ﬁbrosis (F1–2),
and 10 patients (38.5%) had severe liver ﬁbrosis (F3–4), while
only one (5%) of the control group had mild, and 17 (85%)
had severe liver ﬁbrosis (p= 0.002). Fibroscan images of a
patient with F1 and another with F4 ﬁbrosis stage are shown
in Figs. 1 and 2.
On comparing Fibroscan results between cryoglobulin posi-
tive (n= 17) and cryoglobulin negative (n= 9) vasculitis
patients, those with cryoglobulins had a median ﬁbrosis stage
of F2 (range: F0–4), while those without cryoglobulins had a
median ﬁbrosis stage of F1 (range: F1–4), p= 0.990. Ten
patients with cryoglobulinemia (58.82%) had normal–mild
liver ﬁbrosis (F0–2) while 7 (41.12%) had severe ﬁbrosis
(F3–4), while among patients without detectable cryoglobulins
6 (66.67%) had normal–mild and 3 (33.33%) had severe liver
ﬁbrosis, respectively with no statistically signiﬁcant difference
(p= 0.327).
4. Discussion
The association between cryoglobulinemia and severe liver
affection is a controversial issue [1,11,18]. Most studies report-
ing an association between cryoglobulinemia and liver cirrho-
sis have depended on the presence of cryoglobulins in serum
irrespective of the presence of vasculitis, possibly due to the
small number of symptomatic patients [5,11,18], with few
studies speciﬁcally mentioning the association between cryo-
globulinemic vasculitis and liver damage [12,18,20,21]. Agnello
[22] suggested that these differences in patient selection may be
responsible for the controversies regarding the association
between cryoglobulinemia and severe liver damage. Cryoglob-
ulinemia associated with chronic HCV infection has been asso-
ciated with female sex, older age, longer disease duration and
presence of liver cirrhosis in several studies [19,23–25]. It has
been suggested that liver cirrhosis may be the cause for the
excess production of cryoglobulins in chronic HCV infectionroup A and group B concerning the demographic data.
ntrols n= 20 P Group A n= 8 Group B n= 18 P
4 ± 10.5 0.601 57.9 ± 6.9 49.3 ± 7.9 0.014*
1 ± 3.6 0.062 8.4 ± 9.6 7.1 ± 6.3 0.691
3 ± 11.5 0.112 49.5 ± 8.9 41.5 ± 10.8 0.079
Table 2 The clinical and laboratory manifestations of all, group A and group B patients.
All patients (26 patients) n (%) Group A (8 patients) n (%) Group B (18 patients) n (%) P
Arthralgia 16(61.5) 5(52.5) 11(61.1) 1.000
Arthritis 15(57.7) 4(50) 11(61.1) 0.683
Raynaud’s phenomenon 1(3.8) 1(12.5) 0 0.308
Purpura 17(65.4) 1(12.5) 16(88.9) 0.001*
Gangrene 3(11.5) 3(16.7) 0 0.022*
Depression 2(7.7) 1(12.5) 1(27.8) 0.529
Cognitive impairment 1(3.8) 1(12.5) 0 0.308
Brain MRI ﬁndings 2(7.7) 1(12.5) 1(5.6) 0.529
Peripheral neuropathy 9(34.6) 2(25) 7(38.9) 0.667
Mononeuritis multiplex 6(23.1) 6(75) 0 0.001*
IPF 3(11.5) 1(12.5) 2(11.1) 1.000
Cardiac involvement 4(15.4) 1(12.5) 3(16.7) 1.000
Nephritis 3(11.5) 1(12.5) 2(11.1) 1.000
RF positive 11(42.3) 4(50) 7(38.9) 0.683
ANA positive 5(19.3) 1(12.5) 4(22.2) 0.653
Cryoglobulin positive 17(65.4) 5(62.5) 12(66.7) 1.000
Decreased C3 8(30.8) 2(25) 6(33.3) 1.000
Decreased C4 7(26.9) 3(16.7) 4(22.2) 0.149
A: medium-sized vessel vasculitis; B: small-sized vessel vasculitis; IPF: interstitial pulmonary ﬁbrosis; RF: rheumatoid factor; ANA: antinuclear
antibodies, C3: complement component 3; C4: complement component 4.
* Statistically signiﬁcant.
Table 3 The comparison between patients and controls and between group A and group B concerning the laboratory, sonographic
and Fibroscan ﬁndings.
HCV with vasculitis patients n= 26 Controls n= 20 P Group A n= 8 Group B n= 18 P
ALT (U/L) 42 ± 29.4 63.4 ± 46.2 0.08 51.1 ± 32.8 38.4 ± 0.4 0.363
AST (U/L) 38.9 ± 18.3 62.6 ± 44.8 0.036* 42.6 ± 19.7 37.9 ± 18.3 0.577
Total bilirubin (mg/dl) 0.4 ± 0.3 1.6 ± 2.2 0.041* 0.29 ± 0.12 0.45 ± 0.35 0.105
Serum albumin (g/dl) 3.3 ± 0.7 3.1 ± 0.6 0.514 3.0 ± 0.7 3.1 ± 0.7 0.256
PC (%) 92.2 ± 18.9 85.1 ± 14 0.146 82.5 ± 33.4 96.1 ± 5.2 0.288
INR 1.1 ± 0.2 1.3 ± 0.3 0.017* 1.2 ± 0.3 1.1 ± 0.1 0.099
Sonographic ﬁndings: n (%)
Hepatomegaly 11(42.3) 17(85) 0.006* 5(62.5) 6(33.3) 0.091
Coarse liver 8(30.8) 19(95) 0.001* 4(50) 4(22.2) 0.197
Bright liver 7(26.9) 4(20) 0.732 2(25) 5(27.8) 1.000
Focal lesions 2(7.7) 6(30) 0.062 2(25) 0 0.086
Splenomegaly 7(26.9) 11(55) 0.072 4(50) 3(16.7) 0.149
Portal hypertension 4(15.4) 9(45) 0.046* 3(37.5) 1(5.6) 0.072
Fibroscanstage: n (%)
F0 5(19.2) 2(10) 0.446 1(12.5) 4(22.2) 1.000
F1 6(23.1) 0 0.029* 1(12.5) 5(27.8) 0.628
F2 5(19.2) 1(5) 0.212 0 5(27.8) 0.281
F3 3(11.5) 6(30) 0.149 2(25) 1(5.6) 0.215
F4 7(26.9) 11(55) 0.072 4(50) 3(16.7) 0.149
Median 2 4 0.01* 3.5 1.5 0.225
A: medium-sized vessel vasculitis; B: small-sized vessel vasculitis; ALT: alanine aminotransferase; AST: aspartate aminotransferase; PC:
prothrombin concentration; INR: international normalized ratio.
* Statistically signiﬁcant.
190 A.A. Shahin et al.either directly due to immunological changes resulting from
liver dysfunction or altered elimination of immune complexes
by the reticuloendothelial system [24]. Supporting this hypoth-
esis, cryoglobulins have been detected in different chronic liver
diseases [26,27].
In the present study, there was no statistically signiﬁcant dif-
ference between patients and controls in themean age, sex distri-
bution or estimated disease duration. The accurate calculationof disease duration in chronic HCV is difﬁcult and sometimes
impossible since many patients may be asymptomatic [28],
moreover, in the present study, the source of infection was
unknown in themajority of the studied patients.We chose to cal-
culate the disease onset for patients and controls from the date of
diagnosis of HCV infection and for those in whom the develop-
ment of vasculitis preceded the diagnosis of HCV infection from
the onset of vasculitic symptoms.
Figure 1 Fibroscan result of a patient with F1 hepatic ﬁbrosis (5.8 kPa).
Figure 2 Fibroscan result of a patient with F4 hepatic ﬁbrosis (30.3 kPa).
Evaluation of liver condition 191Hepatomegaly with coarse echogenic pattern and portal
hypertension were more frequently found in HCV controls
(p= 0.0006, 0.001 and 0.046, respectively). Liver function tests
revealed signiﬁcantly higher mean serum AST, total bilirubin
and INR in the control group (p= 0.036, 0.041 and 0.017,
respectively). Serum ALT levels were not signiﬁcantly different
between vasculitis patients and the control group, which is in
agreement with Calleja et al. [29]. On Fibroscan, 42.3% of vas-
culitis patients and only one patient of the control group (5%)
had mild liver ﬁbrosis (F1–2), while 38.5% of patients with vas-
culitis had severe liver ﬁbrosis (F3–4) as compared to 85%of the
control group (p= 0.002). Among patients with vasculitis, nosigniﬁcant differences in liver function tests, ultrasonographic
features and severity of liver ﬁbrosis were found between those
with small or medium sized vessel affection. Furthermore, the
degree of liver ﬁbrosis was not signiﬁcantly different between
cryoglobulin positive and negative vasculitis patients.
The frequency of advanced liver ﬁbrosis in HCV vasculitis
patients in this study was comparable to several studies which
reported advanced ﬁbrosis/cirrhosis in 25–44% of their
patients with HCV vasculitis [20,21,29–31], however, in the
present study, the frequency of severe liver affection was signif-
icantly higher in the control group without vasculitis. In con-
trast, Calleja et al. [29] found a much higher incidence of
192 A.A. Shahin et al.cirrhosis in patients with cryoglobulinemic vasculitis as com-
pared to those with chronic hepatitis without detectable cryo-
globulins. Notably, in that study, vasculitis patients had a
signiﬁcantly longer disease duration than the control group
with chronic hepatitis. Saadoun et al. [20] found cryoglobulin-
emia to be independently associated with advanced hepatic
ﬁbrosis. No signiﬁcant differences in the severity of liver dis-
ease were found between symptomatic and asymptomatic
cryoglobulinemia [20,21]. On the other hand, in a 15-year pro-
spective study on 950 chronically infected HCV patients, the
estimated progression rate of liver ﬁbrosis was signiﬁcantly
lower in cryoglobulinemic syndrome (CS) positive than in
MC negative patients. The 15-year cumulative probability of
developing cirrhosis and/or hepatocellular carcinoma was
higher in MC() than in CS(+) patients (24.9% vs. 14.2%,
p< 0.005 and 20.3% vs. 7.5%, p= 0.003, respectively) [32].
It has been hypothesized that the Wa monoclonal RF (Wam-
RF) of type II cryoglobulinemia may be protective against the
progression of liver disease. The HCV, to evade the immune
response, forms complexes with very low density lipoproteins
and enters the hepatocytes through the low density lipoprotein
receptor. By combining with the HCV–VLDL complex, Wam-
RF prevents endocytosis of the virus into the liver cells, and
thus may slow down the progress of liver damage [22].
In conclusion, patients with chronic HCV infection without
vasculitis have worse liver functions and more advanced liver
ﬁbrosis than those with HCV-related vasculitis. Further stud-
ies are needed to identify the different protective mechanisms
of the hepatocytes.
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